A quiet shopping-center shell by North Central Expressway and Exchange Parkway is on track to become BMK Pharma’s U.S. headquarters and a high-tech drug production hub, after the Allen Planning and Zoning Commission voted on Wednesday to recommend a zoning change. If the City Council signs off, the roughly 50,000-square-foot site would be converted into a sterile compounding and manufacturing facility supplying hospitals and clinics.
What the zoning change would allow
The commission voted unanimously to recommend shifting the property’s base zoning from “shopping center” to a “drug and pharmaceutical manufacturing” designation, opening the door to research, design, development, production, storage and sales of pharmaceutical products.
Senior Planner Matt Bechtlufft told commissioners that staff backed the request in part because the building “doesn’t look like your traditional shopping center,” and the plans include a laboratory with a Level 1 biosafety rating. The application also asks to allow electronic manufacturing and a medical clinic on site, according to Community Impact.
What BMK plans
BMK has pitched the Allen property as its U.S. headquarters: a 503B compounding pharmacy and sterile contract development and manufacturing organization expected to produce injectable drugs and other sterile dosage forms, while creating more than 100 skilled jobs, per Dallas Innovates. Company leaders have framed the project as part of a broader “Made in America” push to rebuild domestic sterile drug capacity.
Site, permits and scale
State filings list the project as tenant improvements at Exchange Business Center - Building A, 260 W. Exchange Parkway, covering a 50,864-square-foot buildout and reflecting a construction timeline that began earlier this year, according to project records from the Texas Department of Licensing and Regulation. BMK’s website describes the firm as a 503B outsourcing facility focused on producing sterile compounded medications for hospitals and clinical providers.
What comes next
The Allen City Council is expected to take up the rezoning request at its Aug. 11 meeting, a decision that will determine whether BMK can proceed to occupancy and final inspections, as reported by Community Impact. Residents can review agendas, staff reports and sign up to speak at the public hearing through the city’s meetings portal, per the City of Allen.
Why it matters
The BMK project slots into a broader shift across North Texas, where life-sciences and light manufacturing operations are increasingly filling former retail and office sites. Research firm CBRE has pointed to Dallas–Fort Worth’s expanding life-sciences labor pool and manufacturing potential, factors that economic boosters say helped lure BMK to Allen in the first place.
